Saturday 17 October 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 87.4% and free cash flow fell 579.0%, each against the same quarter a year earlier.
36.74
0.05
+0.14%
Follow LBRX
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
3.56 | 41.44 |
Net Debt/EBITDA |
0.43 | 9.90 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.84 | 1.40 |
Capex/Depreciation |
(13.49) | (0.09) |
| 0.00% | (24.38%) | |
| 0.00% | (14.55%) | |
ROIC |
0.00% | (311.67%) |
Return on Tangible Assets |
(278.85%) | (8.33%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(150.34) | (4.38) |
Cash per Share |
78.21 | 36.70 |
Shareholders Equity per Share |
55.04 | 37.45 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
55.04 | 37.45 |
Free Cash Flow |
(53.82) | (35.26) |
Working Capital |
20.77 | 300.99 |
Capital Expenditures |
(0.77) | (0.05) |
Net Current Asset Value |
15.05 | 296.81 |
| Other line items | ||
Quick Ratio |
3.45 | 39.67 |
Depreciation/Fixed assets |
0.03 | 0.37 |
Cash ROIC |
(112.82%) | (5.91%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(148.19) | (4.38) |
Capex per Share |
(2.15) | (0.01) |
Average Payables |
— | 2.22 |
Average Assets |
— | 173.23 |
Average Common Equity |
— | 103.38 |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates